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 Surgical treatment of patients with peritoneal metastases in combination with Hyperthermic intraperitoneal Chemotherapy 
(HIPEC) and systemic treatments is applied with increasing frequency and, with correct patient qualification, allows for 
obtaining 5-year survival at a level of 32–52%. The conditions necessary for positive results of such treatment include the 
high experience of a given centre, its appropriate infrastructure, and appropriate patient qualification for the procedure. As 
a result of the debate connected with the need to evaluate treatment quality and results, at the request of the Peritoneal 
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of German [5] or French [7] centres, the case of each patient 
treated with the CRS/HIPEC will be reported in this register, 
which is one of the obligatory conditions for quality assurance.
Indications for cytoreductive surgeries and 
HIPEC
Cytoreductive surgery (CRS) and Hyperthermic IntraPEritoneal 
Chemotherapy (HIPEC) are generally recognised methods of 
the treatment of peritoneal metastases (PM) of such tumours 
as: appendiceal malignancy tumours, peritoneal mesothe-
lioma, pseudomyxoma peritonei, and also, in some selected 
cases – peritoneal metastases of colorectal cancer, gastric 
cancer and ovarian cancer.
In the case of pseudomyxoma peritonei, peritoneal me-
sothelioma, primary peritoneal cancer (PPC) and peritoneal 
metastases of appendiceal malignancy tumours, cytoreductive 
surgery in connection with HIPEC are the treatment of choice. 
In the presence of peritoneal metastases of colorectal cancer, 
the CRS/HIPEC procedures are performed in selected cases, in 
whom the Sugarbaker  Peritoneal Cancer Index (PCI), is not hi-
gher than 20 score with concomitant lack of distant metastases, 
with the exception of metachronous liver metastases (up to 3 
resectable lesions) and lung metastases (one single resectable 
lung metastasis). In the case of peritoneal metastases of gastric 
cancer, cytoreductive procedures are performed only in a few 
selected patients in whom the disease stage of peritoneal 
metastases does not exceed 6–8 score in the PCI classification.
In patients with ovarian cancer, the CRS/HIPEC procedures 
are recommended in those with IIIc stage, after neoadjuvant 
chemotherapy in whom there was a positive response to 
systemic treatment.
In the case of patients with other types of cancer in whom 
peritoneal metastases occurred and in patients with resectable 
peritoneal metastases (or metastases in other locations) in 
whom all the possibilities of systemic treatment have already 
been used the CRS/HIPEC procedures can be performed if the-
re is an absence of organ metastases, good general condition 
of the patient, and expected improvement in the condition 
after surgery. The decision concerning the possibility and 
necessity of such treatment is taken by a therapeutic team 
consisting of a surgeon, a clinical oncologist, a radiologist, and 
a pathologist. Cytoreductive surgeries and HIPEC procedures 
should not make up a treatment as such, but rather comprise 
a part of integrated multispecialist therapy, comprising neo-
adjuvant and adjuvant systemic treatment, surgeries, ablations, 
Introduction
Surgical treatment of patients with peritoneal metastases, 
in combination with Hyperthermic IntraPEritoneal Chemo-
therapy (HIPEC), and systemic therapies is currently applied 
with increasing frequency. The results of numerous studies 
have shown that with appropriate patient qualification, 5-year 
survival may reach a level of 32–52% [1–3]. Good treatment 
results depend on the local cancer stage within the peritoneal 
cavity and the possibility of performing a radical cytoreduction 
of the peritoneal metastases.
CytoReductive Surgery (CRS) is very extensive, time-con-
suming and requires a great deal of experience in such proce-
dures on the part of the surgeon. Experience is the outcome 
of the number of cytoreductive procedures performed by 
a given surgeon and also of their skills in large surgeries within 
the abdominal cavity [3, 4]. Gaining experience through an 
increasing number of procedures, called the “learning curve”, 
is evaluated differently depending on the following factors: the 
experience of a given centre, the experience of the surgeon, 
the qualification for the procedure, and the type of tumour. 
The experience of a centre in the pre-surgical and post-surgical 
treatment and management of the patient after extensive 
surgical interventions is equally important [4].
All these issues affect the quality of the procedures, the 
rate of postoperative complications and the resulting mortality, 
and, which is of extreme significance, the length of overall 
survival (OS) and the length of recurrence-free survival (RFS).
In Poland, between 2009 and April 2020, 1056 CRS/HIPEC 
procedures were performed in 7 centres, and in 5 of them 
there were more than 150 procedures/centre conducted. Since 
May 2019, CRS/HIPEC procedures have been reimbursed by 
the National Health Fund, at a level covering the basic costs 
of the surgery, which allows such procedures to be performed 
more frequently in the centres of oncological surgery, general 
surgery, oncological gynaecology and paediatric surgery.
As a result of the debate connected with the need to 
evaluate treatment quality and results, at the request of the 
Peritoneal Cancer Section of the Polish Society of Surgical 
Oncology (PTChO), a joint Quality Assurance Commission 
was set up, consisting of the members of the Polish Surgical 
Society (TChP) and PTChO, whose task will be to evaluate the 
centres performing cytoreductive surgeries regarding all the 
above factors affecting the treatment results in patients with 
peritoneal metastases. To this end, a register of CRS/HIPEC 
procedures was also created, and, following the examples 
Cancer Section of the Polish Society of Oncological Surgery, the conditions for quality assurance were worked out and 
a Quality Assurance Commission was set up for the centres performing cytoreductive procedures and HIPEC procedures 
in the treatment of primary and secondary peritoneal tumours.
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targeted therapies, immunological systemic treatment and 
others, worked out in an individual treatment scheme for 
each patient. In a patient in whom it is possible to carry out 
treatment allowing for a macroscopic resection of a tumour, 
each combined/adjuvant treatment should be performed with 
the intention of a complete cure.
An integral therapeutic action which affects the treatment 
results is the improvement of the nutritional status and respira-
tory efficiency before the onset of therapy and also evaluation 
of comorbidities, made as early as possible. The biological 
condition of the patient should influence the decision about 
the surgery qualification, term and scope.
CRS/HIPEC procedures are burdened with a high rate of 
complications (reaching even 40%) resulting mostly from the 
extensive character of the surgery. Perioperative mortality 
is about 1–4%. Generally, the frequency rate and degree of 
complications connected mostly with CRS/HIPEC procedures 
are comparable with major surgeries such as pancreatic head 
resection (pancreatoduodenectomy). Therefore, the qualifica-
tion for the procedure, preoperative preparation, early posto-
perative care, and patient management after the procedure all 
mean certain expectations from the medical team, comprising: 
experience in major surgeries, comprehensive professional 
preparation, allowing for surgery in all areas of the abdomi-
nal cavity and experience in multi-organ surgery. The scope 
of cytoreduction of the tumour tissue sometimes requires 
extensive organ resections, extensive peritoneal resection and 
long surgical procedures connected with patient hypothermia 
during the surgery or the use of a glucose solution as a perfu-
sion fluid (with the administration of oxaliplatin), which might 
lead to osmolarity disorders, posing a danger  to the central 
nervous system, among other things. That is why CRS/HIPEC 
procedures must be performed in centres which, thanks to an 
appropriate infrastructure and the experience of the surgeons 
and the entire therapeutic team, guarantee the best possible 
and safest therapeutic process.
Conditions allowing for good treatment 
results and the limitation of post-operative 
complications. Learning curve for CRS/HIPEC 
procedures
A condition for the success of CRS/HIPEC procedures is the 
possibility of achieving a complete (CC-0) or nearly comple-
te (CC-1) cytoreduction and the limitation of post-operative 
complications.
Bhatt et al. [7] analysed the treatment results of 384 pa-
tients with primary and secondary peritoneal tumours, treated 
by 8 surgeons: five of them had 10–15 years’ experience in 
oncological surgery, two – 5 to 10 years and one – more than 
15 years; 6/8 had a specialisation in general and oncological 
surgery, whilst 2/8 in surgery of the GI tract.
PCI score ranged from 3 to 36, with 18 average. CC-0 was 
performed in 86.7% patients, and CC-1 in 4.2%, whereas in all 
others – CC-2/3. In 114/384 additionally EPIC (Early Postoperati-
ve Intraperitoneal Chemotherapy) was performed with the use 
of 5FU in 29% and Paclitaxel in 71% patients. 3–5 Clavien-Dindo 
grade 3-5 complications were observed in 27.3% patients. The 
30-day perioperative mortality was 7.3%, and here the most 
frequent cause of mortality was neutropenia-related sepsis. 
The complications were as follows: neutropenia – 13%; ana-
stomotic leakage – 7.8%, obstruction – 7.6%, pulmonary com-
plications – 4.7%, sepsis – 4.4%. Revision surgery was required 
in 21/30 patients. In the conclusions of the study, the authors 
observe that the experience of the surgeons performing the 
CRS/HIPEC procedures is necessary for any improvement in 
the therapy results.
Andreasson et al. [8] evaluated the treatment results of 
128 patients with pseudomyxoma peritonei (PMP) selected 
out of a general number of 307 CRS/HIPEC procedures in the 
treatment of peritoneal metastases. The group was divided 
into two parts: I – patients within the learning curve – 73 
patients, II – patients after the learning curve. The R0/R1 radi-
cality in group I and in group II was 48% vs. 80% (p = 0.0002) 
respectively. Intraoperative bleeding in  group I and in group 
II amounted to 2000 ml vs. 800 ml (p < 0.0001) respectively, 
whilst the length of stay in group I was 18 days, and in group 
II – 16 days (p = 0.016). The 4-year survival was definitely lon-
ger in group II, in comparison with group I – 80% vs. 63% (p = 
0.02). The recurrence free survival (RFS) in group I and group II 
was: 64% and 80%; the difference was clear in spite of the lack 
of statistical significance. Survival was conditioned by basic 
factors, such as: PCI and histopathological result (MCP-L vs. 
MCP-H). The stabilisation of the treatment results in PMP was 
observed after 220+/–10 procedures, which is a larger number 
than generally accepted for other types of peritoneal cancers. 
This is the outcome of a higher PMP stage in PCI score in the 
patients qualified for surgery than in the case of, for example, 
colorectal cancers – the scope of the surgical procedure is 
larger, which is connected with an increased rate of post-
-operative complications.
The learning curve should not only consist in the impro-
vement in surgical skills (although they are of key importance 
for cytoreductive procedures and multi-organ resections), but 
also in the ability to correctly qualify patients for CRS/HIPEC 
procedures. The authors believe that an optimum level of CRS 
stability for a given centre is obtained after 200 procedures 
of this type.
The publication of Chang et al. [9] compared the therapy 
results of patients with peritoneal tumours treated in a centre 
collaborating with a more experienced mentoring centre. In 
the study material, 24 patients had PMP with average PCI score 
of 20.3 (6–39), whilst in 26 patients the metastases of other 
cancers were found in the peritoneum (mostly of colorectal 
cancer) with average PCI 8.7 (2–21). CC-0 was performed in 
80.8% patients with peritoneal metastases of colorectal cancer, 
whilst in patients in PMP, the CC-0 rate was 75%. The average 
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length of stay at the ICU (Intensive Care Unit) was 5 days, whilst 
the average length of hospital stay – 14 days. In the post-ope-
rative period, no III/IV grade complications or deaths were 
observed. In 32% cases there were I/II grade complications. 
29 patients needed blood transfusions, and in PMP patients the 
quantity of transfused blood units was larger than in patients 
with colorectal cancer. The CRS/HIPEC interventions made 
up a complex of various procedures: diagnostic, qualifying, 
preparatory, surgical, oncological and anaesthesiologic. All of 
these translated into the final treatment results. According to 
the authors, in order to get optimum stable therapy results, 
which also includes the limitation of complications and perio-
perative mortality, it is recommended that 90–180 procedures 
within the “learning curve” should be performed in a centre 
which performs CRS/HIPEC procedures. The evaluation of the 
authors’ own results showed the number of procedures wi-
thin the learning curve may be lower, provided that a centre 
is supervised by an “authorising” centre which has adequate 
experience in CRS/HIPEC procedures.
Publications concerning the analysis of the experience 
of a surgeon and a centre performing CRS/HIPEC procedures 
quote the work of Voron et al. [10] extensively. These authors 
list the following risk factors for perioperative complications: 
a patient history of earlier procedures within the abdominal 
cavity, age above 60 years, the stage of the lesions within the 
peritoneal cavity above 12 score in the PCI scale and com-
prising more than 6 regions. In the analysis of the results ob-
tained in their own material, Voron proposes the following 
recommendations for new centres introducing CRS/HIPEC 
procedures: the avoidance of risk factors, the limitation of 
cytoreductive surgeries to only the metastases of colorectal 
cancer, appendix and ovaries and excluding these procedures 
in patients with a peritoneal myxoma or mesothelioma. The 
supervision by surgeons fully trained in CRS/HIPEC is recom-
mended. According to the authors, it is necessary that the 
surgeon’s experience in such procedures should not be fewer 
than 40 CRS procedures, which is the condition for performing 
>70% procedures with complete macroscopic radicality (CC-0), 
and 140 for complete and satisfactory results with regards to 
the reduction of complications, radicality of surgical interven-
tions, and obtaining the best therapy results.
In the study of Polanco et al. [11], the analysis concerned 
the results of treatment with the method in 370 patients with 
the following types of cancer: appendiceal malignancies (282), 
peritoneal mesothelioma (60) and gastric cancer (24), in whom 
peritoneal metastases were diagnosed. The CC-0 radicality was 
obtained in general in 84.2% patients, the 60-day complication 
rate was 30%, whereas perioperative mortality – 1.9%. The eva-
luation of the stage of the lesions with the PCI score showed 
that the higher the PCI score, the larger the rate of non-radical 
surgeries. Causes of serious perioperative complications was a 
high tumour grade, a diagnosis of mesothelioma peritonei, and 
peritoneal metastases of gastric cancer. The authors observed 
that in order to minimise the risk of non-radical surgery and 
to reduce serious perioperative complications, as many as 180 
CRS/HIPEC procedures must be performed in a given centre. 
For the improvement of oncological treatment, the learning 
curve is – according to these authors – 90 procedures. With this 
number of procedures performed, the rate of 2-year survival 
in patients increases. The authors emphasise the necessity of 
performing these procedures in high-volume hospitals as this 
allows these surgeries to be carried out in accordance with 
generally adopted safety criteria.
One of the earlier papers discussing the necessity of ga-
ining experience for the improvement in the surgical treatment 
results in patients with peritoneal metastases comes from 
a Dutch centre [12]. In this study, the treatment results of 
323 patients with peritoneal metastases of colorectal cancer 
(184 patients) and peritoneal myxoma (139 patients) in three 
subsequent 3-year periods were analysed. CC-0 was, in these 
subsequent periods: 35.6%, 48.8% and 65.1%. The difference 
between specific periods was statistically significant (p = 0.012). 
The rate of postoperative complications decreased from 71.2% 
to 34.1% (p < 0.001). A tendency in hospital stay reduction 
was observed,  decreasing from 24 to 17 days in comparison 
between the II and III periods, a feature that was not seen 
between periods I and II. The 2-year survival rate increased 
from 59.7% in period  I, through 61.9% in period II, to 71.7% in 
period III. The authors showed a continual improvement in the 
treatment results, evaluated with regards to the possibility of 
CC-0 resections, was seen after 130 procedures.
The opinions concerning the necessary (and beneficial) 
supervision of a more experienced centre over a centre which 
is at the stage of introducing cytoreductive surgeries, were pre-
sented in the study by Kusamura et al. [13]. The collaboration 
with regards to mentoring assistance allows for shortening the 
learning curve for the CRS/HIPEC procedures and for the reduc-
tion of the initial number of adverse factors connected with 
the procedure, such as: inappropriate patient qualification or 
the qualification of patients with too high a stage of peritoneal 
metastases in relation to the professional experience, which 
results in incomplete cytoreduction, the occurrence of serious 
perioperative complications and a high rate of perioperative 
mortality. This opinion was presented after the analysis of 
the authors’ own materials from an Italian centre which was 
one of the most experienced in the treatment of peritoneal 
metastases [14]. This study evaluated the treatment results of 
420 patients with peritoneal cancers undergoing CRS/HIPEC 
surgeries. The rate of incomplete cytoreductions, serious posto-
perative complications and perioperative mortality were ana-
lysed. The factors affecting the lack of complete cytoreduction 
in a multi-variant analysis were: worse general condition of the 
patients (p = 0.01), PCI > 20 score (p = 0.001), previous systemic 
chemotherapy (p = 0.011), tumour histological type (p = 0.027) 
and the experience gained by a centre – all these factors were 
evaluated with regards to the results of the subsequent 50-per-
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son patient groups (p = 0.042). The factors connected with 
serious perioperative complications in a multivariant analysis 
were: older age (>52 year of age vs. <52 year of age, p = 0.009), 
decreased level of albumins < 3.5g/dL (0.019), PCI > 20 score 
(p = 0.002) and the timespan of the procedure >600 minutes 
vs. <600 minutes (p = 0.025). The occurrence of complications 
was not affected by the experience measured by the number 
of CRS/HIPEC procedures, which can be explained by the ma-
ximum level of complication reduction after the performance 
of 140 procedures. The authors note that such a number of 
CRS/HIPEC procedures allows for obtaining optimum results 
both with regards to the possibility of complete cytoreduction 
and the limitation of serious postoperative complications.
Huang et al. [15] presented the results of a study compri-
sing a group of 800 patients treated with CRS/HIPEC procedu-
res for primary and secondary peritoneal cancers. The study 
subjects were divided into 8 groups, each comprising 100 
patients. The analysis showed an improvement in the treat-
ment results evaluated with 5-year survival between group 
I (the first 100 patients) and group IV (patients 301–400). For 
the metastases of colorectal cancer, the survival was: 15% and 
31% respectively, for PMP – 64% vs. 94%, and for peritoneal 
mesothelioma – 40% vs. 53%. An improvement in the results 
was also seen with regards to a decrease in postoperative 
complications, decrease in the amount of blood transfused and 
decrease in the length of hospital stay. The authors observe 
that the improvement in the treatment results was obtained 
after 200 CRS/HIPEC procedures. Also, the treatment of patients 
with a high stage of peritoneal metastases was reduced from 
PCI < 20 score to PCI < 15 score.
The problem of the effect of the learning curve on the 
treatment results of the patients with peritoneal metastases 
was also the subject of the study carried out by Kuijpers et al. 
[16]. The analysis concerned the results of 372 patients with 
peritoneal metastases treated with CRS/HIPEC in a centre with 
experience in performing cytoreductive surgeries and in a new 
centre introducing such procedures. Mentoring supervision by 
a more experienced centre had a positive effect on the initial 
rate of complete cytoreductions in the new centre, amounting 
to 86% in comparison with 66% in the mentoring centre for 
the first 100 procedures (p < 0.001). This supervision resulted 
also in a limitation of serious postoperative complications 
in comparison with a pioneer centre. The authors observe 
that mentoring supervision allows for shortening the lear-
ning curve, early improvement in the quality of cytoreductive 
procedures and the limitation of perioperative complications.
Expert opinions from the centres with the 
largest experience in cytoreductive and HIPEC 
procedures
The analysis of publications discussing the conditions which 
should be met by a surgeon performing CRS/HIPEC procedu-
res pointed to large discrepancies in indications concerning 
the surgeon’s experience in performing such procedures for 
optimal treatment results and for the reduction of the rate 
of perioperative complications. The required experienced is 
defined as the number of procedures performed ranging 
between 40 and 90, and often depends on the number of 
procedures in a given centre. The experience of a centre, in 
turn, should not be below 90 procedures (up to 200), before 
a centre is considered to meet the required conditions. Taking 
into consideration the influence of the collaboration between 
less experienced and more experienced centres on the decre-
ase of the number of independently performed cytoreductive 
procedures (“from the start”) by a given surgeon and also on 
the experience of the entire centre, the learning curve is not 
homogenous and depends on many factors.
In order to obtain credible expert opinions in the above 
respect, we have asked, in an email, for the opinion of some 
distinguished European experts in treatment of patients with 
peritoneal tumours with CRS/HIPEC procedures; the experts 
were:
1. Professor Beate Rau, Chirurgische Klinik Campus Charite 
Mitte, Berlin, Germany;
2. Professor Marcello Deraco, Director of the Peritoneal Surfa-
ce Malignancies Unit Fondazione IRCCS Istituto Nazionale 
dei Tumori, Milano, Italy, Co-Director of ESPSO European 
School for Peritoneal Surface Oncology;
3. Professor Olivier Glehen, Service de chirurgie digestive et 
endicrinienne, Centre Hospitalier Lyon, France;
4. Professor Vic Verwaal, Aarhus University Hospital, Denmark.
In the opinion of the international experts presented in 
table I, at least 100 to 150 procedures with the CRS/HIPEC 
method are required to be performed in a centre for obtaining 
an optimum quality of cytoreductive procedures. Three experts 
drew attention to the need for performing such procedures 
in high-volume centres. The experience of the entire team is 
necessary, which translates into a minimum number of 25 or 
20–30 procedures per year. Two experts pointed to the need 
to create a training programme in CRS/HIPEC procedures for 
surgeons, whilst all of them suggested the collaboration with 
mentoring centres as an element that is necessary for the 
best results in the new centres. One of the experts observed 
that a database is necessary for continuous improvement in 
the treatment results. Such databases exist in German, French 
and Dutch centres.
The proposal for the quality assurance 
recommendations of the Polish Surgical Society 
and Polish Society of Oncological Surgery 
concerning the necessary criteria for meeting 
the conditions for a Reference Centre 
On the basis of the published data analysis, the experts’ own 
experience and the consultations with the experts from foreign 
centres, a team of surgeons associated in the Peritoneal Tum-
our Section of the Polish Society of Oncological Surgery worked 
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out a model of the conditions necessary for awarding the status 
of reference centre (i.e. one that authorises the procedure) for an 
institution. The results are presented below in table II. 
In the period of creation of specialist centres for the treat-
ment of peritoneal tumours (i.e. combining surgical procedures 
with intraoperative chemotherapy) it is important to appoint 
the Procedure Leader i.e. a surgeon specialising in general 
surgery and/or oncological surgery. Such a person must have 
professional experience in the treatment of peritoneal cavity 
tumours with a full scope of surgeries performed within the 
abdominal cavity. Moreover, the results of surgical treatment in 
cytoreductive and HIPEC procedures will be regularly (annually) 
evaluated, which is supposed to guarantee appropriate quality 
for a given procedure, which is a key element for the treatment 
results in cancer. It is also required to a have a certificate in 
training in the use of HIPEC equipment.
The execution of the quality assurance process in 
CRS/HIPEC centres by the Polish Surgical Society 
and Polish Society of Oncological Surgery 
In order to work out the principles of Quality Assurance, the 
Peritoneal Cancer Section of the Polish Society of Oncological 
Surgery submitted a request to the Management of the Polish 
Surgical Society and Polish Society of Oncological Surgery to 
analyse the proposals presented concerning the conditions 
for the centres and therapeutic teams which must be fulfilled 
for the best possible treatment of patients with peritoneal 
cancers. These proposals were presented and discussed twice 
at meetings with surgeons performing CRS/HIPEC procedures 
and possessing broad experience in extensive surgeries within 
the abdominal cavity. Additionally, each of the individuals 
interested in the debate had the opportunity to present their 
standpoint and conclusions from the discussion in an email. 
Then, after obtaining a positive opinion from the National 
Consultant for General Surgery and National Consultant for 
Oncological Surgery, an application was sent to the Mana-
gements of the Polish Surgical Society and Polish Society of 
Oncological Surgery for the creation of a joint Commission 
whose task would be to verify whether the quality assurance 
conditions in the centres which would like to be audited were 
met. Representatives experienced in CRS/HIPEC procedures 
or in extensive surgeries within the abdominal cavity, two for 
the Polish Surgical Society and two for the Polish Society of 
Oncological Surgery, were nominated.
The centres which obtain a positive opinion from the Qu-
ality Assurance Commission will be entered into the register 
of CRS/HIPEC procedures and will be regularly verified with 
respect to the results of the treatment of patients with peri-
toneal cancers. The centres with less experience (an absence 
of or fewer CRS/HIPEC procedures than the number required 
for Quality Assurance) are obliged to select a reference centre 
which meets all the Quality Assurance requirements and to 
co-operate with them. This is compliant with the opinions of 
international experts and with the published data. Every year, 
the Quality Assurance Commission will analyse the quality of 
cytoreductive procedures with regards to patient qualification 




 of a centre
High-volume 
centre    
The experience  
of a surgical team
Training  
programme
 Collaboration  with a 
mentoring centre
Database 
Prof. B. Rau Yes Yes Yes Yes
Prof. M. Deraco 150 procedures Yes     25 procedures/year Yes
Prof. O. Glehen    20–30 procedures/year Yes Yes
Prof. V. Verwaal 100 procedures Yes Yes Yes
Table II. The quality assurance conditions defined by the Polish Surgical Society and the Polish Society of Oncological Surgery for centres performing cytore-
duction and HIPEC procedures in the treatment of primary and secondary peritoneal tumours 
No. Quality assurance conditions 
1. A hospital performing a full profile of procedures in the peritoneal cavity 
2. Intensive postoperative high dependency unit providing specialist care after  CRS/HIPEC procedures 
3. Hospital infrastructure allowing for the preparation, administration and disposal of cytostatic drugs 
4. Team experienced in the management of patients after chemotherapy 
5. The experience of the surgical team performing CRS/HIPEC procedures in extensive oncological surgeries in the abdominal cavity 
6. Surgical team dedicated to CRS/HIPEC procedures 
7. Surgeon’s experience > 50 procedures CRS CC-0/1 (reference centre) or < 0 procedures CRS CC-0/1 (the centre with contracted co-operation for 
the evaluation of the  CRS/HIPEC procedures with a reference-mentoring centre)
8. Annual rate of CRS/HIPEC surgeries – at least 20–25 procedures 
9. Obligatory registration of all CRS/HIPEC surgeries in the CRS/HIPEC procedures register 
10. Obligatory participation in an annual analysis of the CRS/HIPEC procedures on the basis of the register data
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and the quality of surgical procedures on the basis of the data 
from the CRS/HIPEC procedures register. Each patient who is 
treated with CRS/HIPEC procedures will have to be reported to 
this Register. This is one of the conditions for positive Quality 
Assurance from the Polish Surgical Society and two from the 
Polish Society of Oncological Surgery for a given centre.
This article was prepared by the Peritoneal Cancer Section 
of the Polish Society of Oncological Surgery, which actively 
collaborates with the Polish Surgical Society. This publication 
will be jointly published in Polski Przegląd Chirurgiczny [Polish 
Journal of Surgery] and Nowotwory. Journal of Oncology.
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